Bioventus (NASDAQ:BVS) & RenovoRx (NASDAQ:RNXT) Financial Comparison

Bioventus (NASDAQ:BVS) and RenovoRx (NASDAQ:RNXT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings.

Valuation & Earnings

This table compares Bioventus and RenovoRx”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$581.85 million	1.87	$22.73 million	$0.77	16.77
RenovoRx	$1.12 million	68.10	-$11.17 million	($0.31)	-5.45

Bioventus has higher revenue and earnings than RenovoRx. RenovoRx is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Bioventus and RenovoRx, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0	1	5	0	2.83
RenovoRx	1	0	2	1	2.75

Bioventus currently has a consensus target price of $16.80, indicating a potential upside of 30.13%. RenovoRx has a consensus target price of $8.50, indicating a potential upside of 402.96%. Given RenovoRx’s higher probable upside, analysts clearly believe RenovoRx is more favorable than Bioventus.

Profitability

This table compares Bioventus and RenovoRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bioventus	9.36%	28.08%	9.82%
RenovoRx	-621.71%	-135.11%	-101.91%

Institutional and Insider Ownership

62.9% of Bioventus shares are owned by institutional investors. Comparatively, 3.1% of RenovoRx shares are owned by institutional investors. 33.5% of Bioventus shares are owned by insiders. Comparatively, 9.4% of RenovoRx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Bioventus has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, RenovoRx has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500.

Summary

Bioventus beats RenovoRx on 11 of the 15 factors compared between the two stocks.

About Bioventus

Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body’s natural healing process in the United States and internationally. The company’s portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions include bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company’s restorative therapies comprise an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician’s office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

About RenovoRx

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.